Ixekizumab in the Treatment of Pityriasis Rubra Pilaris (PRP)
Status:
Completed
Trial end date:
2020-01-13
Target enrollment:
Participant gender:
Summary
15 patients with PRP will be treated with ixekizumab for 24 weeks to determine safety and
efficacy. Participants are required to travel to Portland, OR only for the first visit and
week-24 visit. 5 visits in between these times and one follow up visit may be performed by
secure videoconferencing.